773 related articles for article (PubMed ID: 12799406)
1. Impact of HIV infection and HAART on serum lipids in men.
Riddler SA; Smit E; Cole SR; Li R; Chmiel JS; Dobs A; Palella F; Visscher B; Evans R; Kingsley LA
JAMA; 2003 Jun; 289(22):2978-82. PubMed ID: 12799406
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
[TBL] [Abstract][Full Text] [Related]
3. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
[TBL] [Abstract][Full Text] [Related]
4. Effects of highly active antiretroviral therapy on paediatric metabolite levels.
Rhoads MP; Smith CJ; Tudor-Williams G; Kyd P; Walters S; Sabin CA; Lyall EG
HIV Med; 2006 Jan; 7(1):16-24. PubMed ID: 16313288
[TBL] [Abstract][Full Text] [Related]
5. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
Koppel K; Bratt G; Eriksson M; Sandström E
Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
7. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
8. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
9. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010.
Kit BK; Carroll MD; Lacher DA; Sorlie PD; DeJesus JM; Ogden C
JAMA; 2012 Aug; 308(6):591-600. PubMed ID: 22871871
[TBL] [Abstract][Full Text] [Related]
10. Trends in serum lipids and lipoproteins of adults, 1960-2002.
Carroll MD; Lacher DA; Sorlie PD; Cleeman JI; Gordon DJ; Wolz M; Grundy SM; Johnson CL
JAMA; 2005 Oct; 294(14):1773-81. PubMed ID: 16219880
[TBL] [Abstract][Full Text] [Related]
11. Lipids profile among ART-naïve HIV infected patients and men who have sex with men in China: a case control study.
Wang Q; Ding H; Xu J; Geng W; Liu J; Guo X; Kang J; Li X; Jiang Y; Shang H
Lipids Health Dis; 2016 Sep; 15(1):149. PubMed ID: 27600391
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
Muhammad S; Sani MU; Okeahialam BN
Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
14. Trends in lipids and lipoproteins in US adults, 1988-2010.
Carroll MD; Kit BK; Lacher DA; Shero ST; Mussolino ME
JAMA; 2012 Oct; 308(15):1545-54. PubMed ID: 23073951
[TBL] [Abstract][Full Text] [Related]
15. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.
Asztalos BF; Schaefer EJ; Horvath KV; Cox CE; Skinner S; Gerrior J; Gorbach SL; Wanke C
Atherosclerosis; 2006 Jan; 184(1):72-7. PubMed ID: 15935358
[TBL] [Abstract][Full Text] [Related]
17. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.
Langat A; Benki-Nugent S; Wamalwa D; Tapia K; Ngugi E; Diener L; Richardson BA; Melvin A; John-Stewart GC
Pediatr Infect Dis J; 2013 Jul; 32(7):e298-304. PubMed ID: 23385950
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
[TBL] [Abstract][Full Text] [Related]
19. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
[TBL] [Abstract][Full Text] [Related]
20. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
